Swiss medical technology company Ypsomed has announced plans to establish its first U.S. manufacturing facility in Holly Springs, North Carolina, marking a major step in its global expansion strategy and a significant addition to the region’s growing manufacturing ecosystem.
The company will invest around CHF 200 million (approximately USD 220 million) in the project’s first phase, acquiring a 160,000-square-foot facility with room to expand. The site will begin production by the end of 2027, supplying injection systems for the U.S. healthcare market and strengthening Ypsomed’s ability to serve North American customers directly.
Initially, the facility is expected to create around 100 new jobs, with that number projected to grow to about 200 as production scales.
“Establishing our new production site in the United States marks an important step in Ypsomed’s global growth strategy. We have deliberately chosen Holly Springs, a location at the heart of our industry, close to our customers. The cooperative approach of the local authorities, the excellent infrastructure, and the proximity to top-tier universities provide ideal conditions for our future growth. This environment will allow us to attract the skilled workforce we need and to further strengthen our position as a leading supplier of self-injection systems worldwide, while contributing to the security of supply for the U.S. healthcare market,” said Simon Michel, CEO of Ypsomed.
The move reinforces Holly Springs’ emergence as one of North Carolina’s most dynamic life sciences hubs. Already home to global biotech leaders such as Amgen, FUJIFILM Diosynth Biotechnologies, and Catalent, the town has rapidly become a destination for advanced manufacturing investment and workforce development in the life sciences.
“This announcement diversifies the types of companies located here,” said Holly Springs Mayor Sean Mayefskie. “Everyone knows about the global biotech leaders who call Holly Springs home, and Ypsomed will provide needed supplies to contribute to the creation of life-saving medications produced right here in our community.”
The Research Triangle region, home to more than 650 life sciences operations, provides a deep talent pool and integrated ecosystem spanning research, development, device manufacturing, and biomanufacturing—making it a natural choice for Ypsomed’s U.S. debut.
Ypsomed’s Holly Springs site joins a network of facilities across Europe and Asia as part of the company’s multi-year investment in global production capacity. In 2025, Ypsomed opened its first manufacturing plant in Changzhou, China, began expansion of its “Schwerin 2” site in Germany, and is investing CHF 200 million in the enlargement of its Solothurn, Switzerland facility.
Headquartered in Burgdorf, Switzerland, Ypsomed is a leading developer and manufacturer of self-injection systems for liquid medications, partnering with pharmaceutical and biotech companies worldwide. Its portfolio includes pen injectors, autoinjectors, and on-body devices designed to simplify therapy for patients managing chronic conditions.
For North Carolina, the arrival of Ypsomed underscores the state’s growing international influence in advanced manufacturing and healthcare innovation. Holly Springs, in particular, continues to attract life sciences companies that are building the infrastructure of tomorrow’s medicine—from drug development to delivery technologies.
As Ypsomed invests in its first U.S. base, the company not only strengthens its global reach but also deepens the region’s ecosystem of collaboration, innovation, and opportunity.